- Home
- CRNT vs ALXO Comparison
CRNT vs ALXO Comparison
Compare CRNT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNT | ALXO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.1M | 240.8M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRNT | ALXO |
|---|---|---|
| Price | $2.52 | $1.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.50 | $3.50 |
| AVG Volume (30 Days) | 444.8K | ★ 967.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.11 | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $0.41 |
| 52 Week High | $2.84 | $2.66 |
Technical Indicators
Market Signals| Indicator | CRNT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 37.14 |
| Support Level | $2.25 | $1.60 |
| Resistance Level | $2.56 | $2.30 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 88.79 | 17.78 |
Price Performance
Historical ComparisonAbout CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.